CelLBxHealth (FRA:DWV) Total Liabilities: €6.16 Mil (As of Dec. 2025)


What is CelLBxHealth Total Liabilities?

CelLBxHealth FRA:DWV +5.88% Total Liabilities is €6.16 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CelLBxHealth's Total Liabilities for the quarter that ended in Dec. 2025 was €6.16 Mil.

CelLBxHealth's quarterly Total Liabilities declined from Dec. 2024 (€8.47 Mil) to Jun. 2025 (€7.52 Mil) and declined from Jun. 2025 (€7.52 Mil) to Dec. 2025 (€6.16 Mil).

CelLBxHealth's annual Total Liabilities declined from Dec. 2023 (€9.57 Mil) to Dec. 2024 (€8.47 Mil) and declined from Dec. 2024 (€8.47 Mil) to Dec. 2025 (€6.16 Mil).

CelLBxHealth Total Liabilities Historical Data

* Premium members only.

The historical data trend for CelLBxHealth's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CelLBxHealth Total Liabilities Chart

CelLBxHealth Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.22 11.27 9.57 8.47 6.16

CelLBxHealth Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9.57 10.02 8.47 7.52 6.16

CelLBxHealth Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CelLBxHealth's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.31+(1.143+0.707
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.16

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=14.387-8.227
=6.16

CelLBxHealth's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=4.31+(1.143+0.707
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=6.16

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=14.387-8.227
=6.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €6.16 Mil mean?
CelLBxHealth (FRA:DWV) has a Total Liabilities of €6.16 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CelLBxHealth and its competitors.
Is CelLBxHealth's Total Liabilities too high?
CelLBxHealth's current Total Liabilities is €6.16 Mil.
How does CelLBxHealth's Total Liabilities compare to TMO and DHR?
CelLBxHealth's Total Liabilities of €6.16 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CelLBxHealth and its competitors. CelLBxHealth's current Total Liabilities is €6.16 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CelLBxHealth stock overvalued right now?
CelLBxHealth (FRA:DWV) has a current Total Liabilities of €6.16 Mil. The current Total Liabilities is €6.16 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For CelLBxHealth (FRA:DWV), the current Total Liabilities is €6.16 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CelLBxHealth Business Description

Other Exchanges ANPCF:USACLBX:UK
Address 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, GBR, GU2 7AF
CelLBxHealth PLC is active in the healthcare sector in the United Kingdom. The Company's principal trading activity is undertaken in relation to the development and commercialization of the Parsortix cell separation system, with deployment in liquid biopsy that is non-invasive cancer diagnostics. It is a medical diagnostic company specializing in the development of pioneering products in cancer diagnostics. Its patented Parsortix technology can potentially treat and diagnose various forms of cancer. The Parsortix system can capture and harvest CTCs from patient blood. Its geographical segments include Europe and North America, of which the majority of its revenue is generated from Europe.